VEGFA and neoplasm: In addition to its ability to reduce lung metastases, SLT-VEGF treatment also inhibited post-surgical tumor recurrence (0/15 in SLT-VEGF treated vs. 4/10 in control mice, p = 0.007) and improved survival (p = 0.002, Figure 5B).